Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Not everyone needs to reach the maximum dose of 15 mg
Marc Dunoyer, the companys rare disease head, in a statement called Ultomiris a transformative treatment option for NMOSD, with the potential to eliminate relapses with a convenient dosing schedule every eight weeks. The approval was backed by data from a Phase III trial that met its primary efficacy endpoint, preventing relapse in all 58 treated patients over a median of 73.5 weeks, compared to 20 relapses in the placebo arm of a trial for AstraZenecas other NMOSD therapy Soliris
Figure 5 Compare to the MET group, the GO functional classification and enrichment analysis of differentially expressed genes in the control group are shown in Figure 5B
Preclinical cartilage evidence Kwon and Park 2015 in Annals of Clinical and Laboratory Science reported that intra-articular AOD-9604 plus hyaluronic acid in a rabbit knee osteoarthritis model improved cartilage histology and reduced lameness compared with hyaluronic acid alone
